External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Global Health (Medanta) / Equity Bottom-Up

<ul><li>We initiate coverage on Global Health Ltd (MEDANTA) with a BUY recommendation and DCF-based Target Price (TP) of Rs 1,475/share (EV/EBITDA of 26.5x FY27E EBITDA), implying an upside of 25% from the CMP.</li><li>MEDANTA boasts a robust Brand Equity, established by Dr. Trehan, a globally recognized cardiovascular and cardiothoracic surgeon.</li><li>The company has fortified its position with a strong moat, providing the highest standard of care and specializing in high-complexity work. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We initiate coverage on Global Health Ltd (MEDANTA) with a BUY recommendation and DCF-based Target Price (TP) of Rs 1,475/share (EV/EBITDA of 26.5x FY27E EBITDA), implying an upside of 25% from the CMP.MEDANTA boasts a robust Brand Equity, established by Dr. Trehan, a globally recognized cardiovascular and cardiothoracic surgeon.The company has fortified its position with a strong moat, providing the highest standard of care and specializing in high-complexity work. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Global Health Ltd - Highest-Standard Care; High Complexity Work